Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
Feature|Articles|February 20, 2026
Understanding the Biological and Social Complexities of Triple-Negative Breast Cancer
Author(s)Sabrina Serani
Fact checked by: Samilia Obeng-Gyasi, MD, MPH, Paige Britt
How ancestry, neighborhood stress and chemo side effects shape TNBC outcomes—and why immunotherapy and tailored care can narrow survival gaps.
Advertisement
Advertisement
In the landscape of oncology, triple-negative breast cancer (TNBC) remains one of the most challenging subtypes to treat due to its aggressive nature and the lack of traditional hormonal targets. However, for Samilia Obeng-Gyasi, MD, MPH, a surgical oncology specialist at The James, The Ohio State University Comprehensive Cancer Center, the challenge is not just biological; it is deeply rooted in ancestry, social environment, and patient experience.
Related to this article
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of June 25, 2027.
Advertisement
Advertisement